Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:CAR_T-cell_therapy
|
| gptkbp:administered_by |
intravenous infusion
|
| gptkbp:are_part_of |
clinical trial protocols
ongoing research initiatives personalized medicine approaches |
| gptkbp:associated_with |
cytokine release syndrome
immune response modulation improved survival rates |
| gptkbp:can_be_combined_with |
checkpoint inhibitors
|
| gptkbp:can_be_engineered_to_express |
multiple CARs
|
| gptkbp:can_be_produced_using |
gptkb:CRISPR_technology
|
| gptkbp:can_be_used_in |
clinical settings
|
| gptkbp:can_be_used_to_target |
tumor-associated antigens
|
| gptkbp:can_cause |
neurotoxicity
|
| gptkbp:can_involve |
genetic modification
patient selection criteria |
| gptkbp:can_lead_to |
tumor regression
|
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:clinical_use |
gptkb:immunotherapy
|
| gptkbp:developed_by |
gptkb:T_cells
various research institutions patient's own immune cells |
| gptkbp:development |
other hematological malignancies
|
| gptkbp:engineered_with |
chimeric antigen receptor (CAR)
|
| gptkbp:enhances |
quality of life
antitumor immunity response rates in refractory cases |
| gptkbp:has_a_focus_on |
translational research.
|
| gptkbp:has_research_areas |
biomarker identification
|
| https://www.w3.org/2000/01/rdf-schema#label |
GD2-specific CAR T cells
|
| gptkbp:investigates |
combination therapies
|
| gptkbp:is_associated_with |
immunogenicity concerns
|
| gptkbp:is_evaluated_by |
safety and efficacy
|
| gptkbp:is_monitored_by |
adverse effects
|
| gptkbp:is_studied_for |
long-term effects
biological markers |
| gptkbp:is_targeted_at |
monoclonal antibodies
|
| gptkbp:may_be_used_in_conjunction_with |
radiation therapy
|
| gptkbp:mechanism_of_action |
recognizing GD2 on tumor cells
|
| gptkbp:occurs_in |
expansion in vitro
|
| gptkbp:potential_side_effects_include |
fatigue
fever neurological symptoms hypotension |
| gptkbp:potential_to_treat |
other solid tumors
|
| gptkbp:requires |
regulatory approval
supportive care post-infusion monitoring leukapheresis hospitalization post-infusion preconditioning chemotherapy |
| gptkbp:research_focus |
improving persistence
|
| gptkbp:show_activity_against |
tumor microenvironment
|
| gptkbp:show_efficacy_in |
pediatric cancers
|
| gptkbp:show_potential_in |
adult cancers
|
| gptkbp:show_promise_in |
relapsed neuroblastoma
|
| gptkbp:target_audience |
children with high-risk neuroblastoma
|
| gptkbp:targets |
GD2 antigen
|
| gptkbp:type_of |
adoptive cell transfer therapy
|
| gptkbp:used_in |
treatment of neuroblastoma
|
| gptkbp:utilizes |
viral vectors for transduction
|
| gptkbp:bfsParent |
gptkb:GD2_ganglioside
|
| gptkbp:bfsLayer |
8
|